Pagano et al identified risk factors for invasive fungal infection (IFI) in patients with chronic lymphoproliferative disorders. The authors are members of SEIFEM (Sorveglianza Epidemiologica Infezioni Fungine nelle Emopatie Maligne) Group in Italy.
Patient selection: CLL, multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's disease
Intermediate risk factors:
(1) more aggressive or intensive chemotherapy, including multiple lines of therapy
(2) relapsed, refractory or advanced disease
Low risk:
(1) conventional chemotherapy
Other risk factors:
(1) immunosuppression
(2) severe and prolonged neutropenia
(3) history of previous invasive fungal infection
To read more or access our algorithms and calculators, please log in or register.
Specialty: Infectious Diseases, Hematology Oncology
